Cargando…
HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation
BACKGROUND: The introduction of direct-acting antivirals (DAA) for HCV has led to high rates of HCV eradication. Treatment of patients awaiting liver transplantation (LT) has been controversial. Recent data suggests that DAA treatment may accelerate recurrent HCC. The impact of DAA on delisting for...
Autores principales: | Emamaullee, Juliet A., Bral, Mariusz, Meeberg, Glenda, Montano-Loza, Aldo J., Bain, Vincent G., Burak, Kelly Warren, Bigam, David, Shapiro, A. M. James, Kneteman, Norman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354133/ https://www.ncbi.nlm.nih.gov/pubmed/30775356 http://dx.doi.org/10.1155/2019/2509059 |
Ejemplares similares
-
What Is the Role of Body Composition Assessment in HCC Management?
por: Radu, Pompilia, et al.
Publicado: (2022) -
Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
por: Hosui, Atsushi, et al.
Publicado: (2021) -
HCC, diet and metabolic factors: Diet and HCC
por: Montella, Maurizio, et al.
Publicado: (2011) -
APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation
por: Kanda, Tatsuo, et al.
Publicado: (2019) -
Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC
por: De Battista, Davide, et al.
Publicado: (2021)